Advertisement

Search Results

Advertisement



Your search for The A matches 31922 pages

Showing 51 - 100


Information-Blocking Proposal Helps Protect Reproductive Health Information, Patient Preferences

The Association for Clinical Oncology (ASCO) submitted comments to the Office of the National Coordinator for Health Information Technology in response to the Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) proposed...

Katherine Van Loon Named Editor-in-Chief of JCO Global Oncology

Katherine Van Loon, MD, MPH, has been appointed as the next Editor-in-Chief of JCO Global Oncology (JCO GO). JCO GO is an online-only, open-access ASCO journal focusing on cancer research, care, and delivery in low-resource countries and settings. The journal aims to address the challenges faced...

hepatobiliary cancer

Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma

The National Medical Products Administration (NMPA) of China has accepted a supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination with the multikinase inhibitor anlotinib for the first-line treatment of advanced hepatocellular carcinoma...

cns cancers

Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor

The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier...

breast cancer
issues in oncology
genomics/genetics

Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer

Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...

head and neck cancer

Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma

In a Chinese single-center phase II trial reported in The Lancet Oncology, Lin et al found that the addition of perioperative toripalimab to concurrent chemoradiotherapy was active in patients with newly diagnosed high-risk stage III to IVa locoregionally advanced nasopharyngeal carcinoma with...

hematologic malignancies
issues in oncology

Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists

Participants of the American Society of Hematology (ASH) Minority Recruitment Initiative had lower attrition rates in graduate and medical programs, were more likely to pursue a career in hematology, and had high levels of engagement at ASH beyond their participation in the program, according to a...

gynecologic cancers

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology by Classe et al, the addition of hyperthermic intraperitoneal chemotherapy to complete cytoreductive surgery appeared to significantly improve overall survival in patients with...

sarcoma

Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset

The p53-MDM2 inhibitor siremadlin given with the CDK4/6 inhibitor ribociclib showed activity in a subset of patients with well-differentiated/dedifferentiated liposarcomas enrolled in the biology-driven adaptive phase II MEGAMOST Ribociclib/HDM201 basket trial.1 MEGAMOST was designed to evaluate...

lung cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...

hepatobiliary cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also approved ...

immunotherapy

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

In a retrospective cohort study reported in The Lancet Oncology, Miller et al found that ICI treatment for cancer had similar efficacy and reduced toxicity in Black patients vs White patients in the U.S. Veterans Health Administration (VHA) system. As stated by the investigators, “Black patients...

skin cancer

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monotherapy in immune checkpoint inhibitor treatment–naive patients with unresectable or metastatic...

cns cancers
issues in oncology

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment

An international, multidisciplinary team of neuro-oncology researchers and physicians has developed new clinical practice recommendations for the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer. The guidelines were described in...

breast cancer
issues in oncology

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics. Background Prior research has revealed that firefighters have significantly...

breast cancer

Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer

Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast...

hematologic malignancies

ASH to Present 2024 Honorific Awards at Annual Meeting

The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition, being held December 7–10 in San Diego. “ASH is honored to recognize these outstanding...

issues in oncology

Project Facilitate: 5 Years of Progress, Outreach, and Service

OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Lieutenant Commander Mitchell Chan, PharmD, BCPS, Team Lead and Clinical Analyst, Lieutenant Cameron Wilson, PharmD, BCPS, BCCCP, ...

breast cancer

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...

solid tumors
issues in oncology
thyroid cancer
skin cancer

Suicide-Related Mortality in Male AYA Cancer Survivors

Investigators have found that among all cancer survivors, male adolescents and young adults (AYAs) may have the highest rate of suicide-related mortality, according to a recent study published by Matsuo et al in JAMA Network Open. Cancer is becoming more common among young patients, and cancer...

lymphoma

Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma

“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...

lung cancer

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

Neoadjuvant chemotherapy with vs without nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the International...

pancreatic cancer

Performance of First-Line Chemotherapy Regimens in Unresectable Advanced or Metastatic Pancreatic Cancer

In a meta-analysis reported in The Lancet Oncology, Mastrantoni et al identified first-line chemotherapy regimens associated with better outcomes in patients with unresectable advanced or metastatic pancreatic cancer. Study Details  The Bayesian network analysis included 79 randomized controlled...

hematologic malignancies
solid tumors
immunotherapy
genomics/genetics
issues in oncology

New Technique May Allow for Visualization of CAR T Cells Postinjection

The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...

breast cancer
solid tumors
genomics/genetics
issues in oncology

AI Tool May Detect Cancer Gene Signatures in Biopsy Images

Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature...

pancreatic cancer

Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer

A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to ...

solid tumors
issues in oncology

Cancer-Specific Mortality Trends Among U.S. Asian and Pacific Islander Populations

In a study reported in JAMA Network Open, Zhu et al found that cancer-specific mortality rates have decreased overall among U.S. Asian and Pacific Islander populations during recent years, although increases in cancer-specific mortality have been reported for some cancers. Study Details The...

sarcoma

Addition of Pembrolizumab to Radiation Therapy and Surgery in Stage III Soft-Tissue Sarcoma of the Extremity

In a phase II trial (SU2C-SARC032) reported in The Lancet, Mowery et al found that the addition of perioperative pembrolizumab to preoperative radiation therapy and surgery improved disease-free survival in patients with stage III soft-tissue sarcoma of the extremity. Study Details In the...

colorectal cancer

Onvansertib With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Ahn et al found the combination of the PLK1 inhibitor onvansertib with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab showed activity in the second-line treatment of KRAS-mutant metastatic colorectal cancer....

prostate cancer

Study Identifies New Approach to Overcome Docetaxel Resistance in Patients With Advanced Prostate Cancer

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other targets to treat prostate cancer are still necessary to prolong life and slow the progression of...

gastroesophageal cancer

Neoadjuvant Chemoradiation Followed by Immunochemotherapy and Surgery May Improve Outcomes in Esophageal Cancer

A phase II clinical trial investigating the safety and efficacy of a triple combination of radiation, chemotherapy, and immunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma found that the therapy was effective in shrinking tumors, allowing for surgery, and ...

skin cancer
immunotherapy
issues in oncology

Immunotherapy Combination for Cutaneous Melanoma

Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings supported the development of vidutolimod for...

solid tumors
issues in oncology

Novel Liquid Biopsies and Cancer Detection

Researchers may have uncovered a novel strategy to detect cancer cells with a liquid biopsy that’s designed to be simpler, faster, and more informational than current methods, according to a recent study published by Walker et al in the nanoscience publication Small.  Study Methods and Results In...

head and neck cancer

Enfortumab Vedotin in Previously Treated Advanced Head and Neck Cancer

In a phase II trial (EV-202) reported in the Journal of Clinical Oncology, Swiecicki et al found that the antibody-drug conjugate enfortumab vedotin showed activity in heavily pretreated patients with recurrent or metastatic head and neck cancer (HNC). Study Details In the study, 46 patients who...

cns cancers

Addition of Veliparib to Temozolomide in Newly Diagnosed MGMT-Methylated Glioblastoma

In a phase II/III trial reported in JAMA Oncology, Sarkaria et al found that the addition of veliparib to temozolomide did not improve overall survival in patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation. Study Details In the double-blind Alliance for Clinical Trials...

bladder cancer
immunotherapy
issues in oncology

Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care

Recent advances in urothelial carcinoma treatments may offer a path to curative care for more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published by Milowsky in The New England Journal of Medicine. The findings indicated that...

solid tumors
thyroid cancer
lung cancer
gynecologic cancers
colorectal cancer

Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?

Just 50% of patients with early-onset cancers may report discussing fertility preservation options with their physicians prior to receiving oncology treatments, according to a recent study published by Keller et al in JAMA Network Open. Background “From an early-onset cancer diagnosis through to...

solid tumors
bladder cancer
kidney cancer
gastroesophageal cancer

In Case You Missed It: Roundup From ESMO Congress 2024

In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential...

supportive care
issues in oncology

Exploring Issues in Oncofertility

  “Cancer in young adults is more complicated in part [because of the risk of] infertility and premature menopause,” commented Ann H. Partridge, MD, MPH, FASCO, Interim Chair, Department of Medical Oncology; the Eric P. Winer, MD Chair in Breast Cancer Research, Dana-Farber Cancer Institute; and ...

prostate cancer

Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer

In a prospective analysis reported in JAMA Network Open, Patel et al found that long-term health-related quality of life (HRQOL) was poorer among patients with prostate cancer who received postprostatectomy radiotherapy vs those who did not, with little difference observed among patients with early ...

breast cancer

Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer

As reported in the Journal of Clinical Oncology by Jensen et al, the final analysis of the phase III Danish DBCG07-READ trial showed improved 10-year outcomes with the addition of epirubicin to docetaxel/cyclophosphamide adjuvant therapy in patients with TOP2A-normal breast cancer. The primary...

lymphoma

Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma

In a phase I study reported in The Lancet Oncology, Maruyama et al found that valemetostat—a novel dual inhibitor of EZH2 and EZH1—showed activity in patients with relapsed or refractory non-Hodgkin lymphoma. Study Details In the study, 90 patients from sites in Japan and the United States were...

bladder cancer
prostate cancer
neuroendocrine tumors
immunotherapy

Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers

Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine....

issues in oncology

Medical-Legal Partnerships: A Promising Innovation in Oncology

Beyond the physical toll of the disease and its treatments, cancer often presents a host of legal and social issues that can significantly worsen a patient’s well-being and treatment outcomes. This column explains how medical-legal partnerships can offer a powerful tool to address these challenges ...

solid tumors
genomics/genetics

FDA Approves Novel Companion Diagnostic Assay

Caris Life Sciences announced that the U.S. Food and Drug Administration (FDA) has approved MI Cancer Seek for use as a companion diagnostic assay to identify patients with cancer who may benefit from targeted therapies. Caris Life Sciences is a next-generation artificial intelligence techbio...

issues in oncology

Effect of Smoking Cessation Intervention on Survival After a Cancer Diagnosis

In a single-institution study reported in JAMA Oncology, Cinciripini et al found that patients with cancer who quit smoking after a smoking cessation intervention had improved overall survival after cancer diagnosis. Study Details and Results The study involved data on 4,526 patients who were...

prostate cancer

Study Finds Long-Term Risks Associated With Prostate Cancer Treatment and Highlights the Importance of Counseling Prior to Screening and Treatment

A large cohort study investigating the long-term treatment-related adverse effects and complications from prostate cancer treatment compared to an untreated control group has found that treatment was associated with higher rates of 10 potential complications in the 12 years after treatment. Given...

cns cancers

Study Finds In Situ Vaccination Using Tumor Treating Fields Plus Immune Checkpoint Inhibitors Extended Survival in Patients With Glioblastoma

A small study investigating tumor treating fields—an antimitotic electric fields therapy—in combination with pembrolizumab and temozolomide for the treatment of patients with glioblastoma was found to be a promising strategy, especially in patients with substantial residual tumor, according to the...

issues in oncology
breast cancer
genomics/genetics

Breast Cancer Vaccine Could Be Preventive, Well Tolerated in High-Risk Patients

Researchers have uncovered insights into a novel investigational vaccine aimed at preventing triple-negative breast cancer. The findings by Rhoades et al were presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting (Abstract 631) and simultaneously published in the Journal...

breast cancer

Addition of Inavolisib to Palbociclib/Fulvestrant in PIK3CA-Mutated Advanced Breast Cancer

In a phase III trial (INAVO120) reported in The New England Journal of Medicine, Turner et al found that the addition of inavolisib to palbociclib/fulvestrant improved progression-free survival in the first-line treatment of patients with PIK3CA-mutated advanced breast cancer. Inavolisib is an...

Advertisement

Advertisement




Advertisement